KELI Therapeutics exhibits at BIX 2026 in Seoul
KELI presented its cartilage and exosome platforms from its own booth at BIX 2026 in Seoul and met Korean biotech and pharmaceutical companies on licensing and joint development.

Clinical progress, funding validation, and manufacturing development across KELI's pipeline.
KELI presented its cartilage and exosome platforms from its own booth at BIX 2026 in Seoul and met Korean biotech and pharmaceutical companies on licensing and joint development.

KELI Therapeutics completed its participation in bio:cap 2026 — the Life Science & AI Investival, held 9–11 June 2026 in Berlin — presenting KELI-101 and its seed round to life science investors, biotech industry leaders, and strategic partners from across Europe and beyond, operating from its dedicated exhibition stand at Booth 19A.
EU clinical trial number 2026-527099-98-00 was assigned in May 2026. KELI-101: clinical trial application Q4 2026; first patient planned Q2 2027.
External source€2.5M EIC Accelerator grant.
KELI Therapeutics has signed a strategic manufacturing agreement with Bramble Bio (a FamiCord AG CDMO) to support GMP manufacturing scale-up and technology transfer for KELI-101, its placental MSC therapy for acute kidney injury following cardiac surgery. Technology transfer is currently in progress.
External sourceRECARTA is approved under EU Hospital Exemption in Lithuania, with product-specific ATMP manufacturing permit No. 25. Treatments start in January 2027 at Gijos Klinikos, Kaunas.
For media enquiries, interview requests, or investor relations information, contact the KELI communications team directly.